Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Taiwan Biomateiral Co's Net Margin % or its related term are showing as below:
ROCO:6649'
s Net Margin % Range Over the Past 10 Years
Min: -6029.98 Med: -210.08 Max: 26.74
Current: 26.74
ROCO:6649's Net Margin % is ranked better than 93.87% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs ROCO:6649: 26.74
Taiwan Biomateiral Co (ROCO:6649) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Taiwan Biomateiral Co Net Margin % Related Terms
Taiwan Biomateiral Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Taiwan Biomateiral Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6649 vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Taiwan Biomateiral Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Biomateiral Co Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Biomateiral Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Taiwan Biomateiral Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Biomateiral Co (ROCO:6649) has a Net Margin % of 8.13% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Taiwan Biomateiral Co and its competitors. According to the industry distribution chart, Taiwan Biomateiral Co ranks #50 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 6.1%.
Is Taiwan Biomateiral Co's Net Margin % too high?
Taiwan Biomateiral Co's current Net Margin % is 8.13%. The Medical Devices & Instruments industry median Net Margin % is 2.07. Taiwan Biomateiral Co's value of 8.13% is 292.8% above this industry median. Based on the distribution chart, Taiwan Biomateiral Co ranks #50 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Taiwan Biomateiral Co has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Biomateiral Co's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Biomateiral Co ranks #50 out of 816 companies for Net Margin %. This places Taiwan Biomateiral Co in the top 6% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.07. Taiwan Biomateiral Co's value of 8.13% is 292.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Biomateiral Co's current Net Margin % of 8.13% is 292.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Taiwan Biomateiral Co and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Biomateiral Co's current Net Margin % is 8.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Biomateiral Co stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Biomateiral Co (ROCO:6649) is currently considered Possible Value Trap. The stock's GF Value™ is NT$77.96, compared to a current price of NT$37.75 — trading 51.6% below its estimated fair value. The current Net Margin % is 8.13% and 292.8% above the Medical Devices & Instruments industry median of 2.07. Taiwan Biomateiral Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Taiwan Biomateiral Co (ROCO:6649), the current Net Margin % is 8.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Biomateiral Co (ROCO:6649) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Biomateiral Co stock appears to be undervalued.
The current stock price of NT$37.75 is trading 51.6% below its estimated GF Value™ of NT$77.96.
GuruFocus considers Taiwan Biomateiral Co to be Possible Value Trap.
Key valuation signals for ROCO:6649:
Net Margin %: 8.13%
GF Value™: NT$77.96 vs. price of NT$37.75 (51.6% below fair value)
Industry Position: 292.8% above the Medical Devices & Instruments median (#50 of 816)
No single metric tells the full story. See the ROCO:6649 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Biomateiral Co Ltd is an applied technology Research and Development Institute in Taiwan. It is engaged in the research and development and sales of implantable medical devices. The company's products include Foamagen, stroke interventional treatment devices.
74GF Score
Get the complete analysis for ROCO:6649
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6649 has been successfully added to your 
